These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 11884967)

  • 1. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.
    Trach DD; Cam PD; Ke NT; Rao MR; Dinh D; Hang PV; Hung NV; Canh DG; Thiem VD; Naficy A; Ivanoff B; Svennerholm AM; Holmgren J; Clemens JD
    Bull World Health Organ; 2002; 80(1):2-8. PubMed ID: 11884967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
    Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
    Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.
    Saha A; Chowdhury MI; Khanam F; Bhuiyan MS; Chowdhury F; Khan AI; Khan IA; Clemens J; Ali M; Cravioto A; Qadri F
    Vaccine; 2011 Oct; 29(46):8285-92. PubMed ID: 21907255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial.
    Kanungo S; Paisley A; Lopez AL; Bhattacharya M; Manna B; Kim DR; Han SH; Attridge S; Carbis R; Rao R; Holmgren J; Clemens JD; Sur D
    Vaccine; 2009 Nov; 27(49):6887-93. PubMed ID: 19761838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Community trial for safety and immunogenicity of oral-administered lyophilized rBS-WC cholera vaccine].
    Chen Q; Yu S; Wang Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 1996 Nov; 30(6):330-3. PubMed ID: 9388905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response.
    Mahalanabis D; Ramamurthy T; Nair GB; Ghosh A; Shaikh S; Sen B; Thungapathra M; Ghosh RK; Pazhani GP; Nandy RK; Jana S; Bhattacharya SK
    Vaccine; 2009 Jul; 27(35):4850-6. PubMed ID: 19523608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine.
    Jertborn M; Svennerholm AM; Holmgren J
    Vaccine; 1996 Oct; 14(15):1459-65. PubMed ID: 8994322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of cholera and rise of novel mucosal vaccine.
    Yamamoto T
    Jpn J Infect Dis; 2000 Oct; 53(5):181-8. PubMed ID: 11135702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults.
    Anh DD; Canh DG; Lopez AL; Thiem VD; Long PT; Son NH; Deen J; von Seidlein L; Carbis R; Han SH; Shin SH; Attridge S; Holmgren J; Clemens J
    Vaccine; 2007 Jan; 25(6):1149-55. PubMed ID: 17055622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bivalent oral cholera vaccine in participants aged 1 year and older in the Dominican Republic: A phase III, single-arm, safety and immunogenicity trial.
    Cordero De Los Santos L; Feris-Iglesias J; Aloysia D'Cor N; Midde VJ; Patnaik BN; Thollot Y; Rasuli A; Desauziers E
    Hum Vaccin Immunother; 2018 Jun; 14(6):1403-1411. PubMed ID: 29470934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
    Raghava Mohan V; Raj S; Dhingra MS; Aloysia D'Cor N; Singh AP; Saluja T; Kim DR; Midde VJ; Kim Y; Vemula S; Narla SK; Sah B; Ali M
    PLoS One; 2019; 14(6):e0218033. PubMed ID: 31211792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation in tablets of a cholera whole cells inactivated vaccine candidate.
    Talavera A; Año G; Pino Y; Castaño J; Uribarri E; Riverón L; Gil S; Fernández S; Cedré B; Valmaseda T; Pérez JL; Infante JF; García L; Sierra G
    Vaccine; 2006 Apr; 24(16):3381-7. PubMed ID: 16460846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children.
    Taylor DN; Cárdenas V; Perez J; Puga R; Svennerholm AM
    Am J Trop Med Hyg; 1999 Dec; 61(6):869-73. PubMed ID: 10674661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of travellers' diarrhoea by WC/rBS oral cholera vaccine in young, high-risk travellers.
    Torrell JM; Aumatell CM; Ramos SM; Mestre LG; Salas CM
    Vaccine; 2009 Jun; 27(30):4074-7. PubMed ID: 19376179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines.
    Capeding MRZ; Gonzales MLAM; Dhingra MS; D'Cor NA; Midde VJ; Patnaik BN; Thollot Y; Desauziers E
    Hum Vaccin Immunother; 2017 Oct; 13(10):2232-2239. PubMed ID: 28910563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired immune response to natural infection as a correlate of vaccine failure in a field trial of killed oral cholera vaccines.
    Clemens J; Rao M; Sack D; Ahmed F; Khan MR; Chakraborty J; Kay B; Huda S; Yunus M; van Loon F
    Am J Epidemiol; 1995 Oct; 142(7):759-64. PubMed ID: 7572947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of mass oral cholera vaccination in Beira, Mozambique.
    Lucas ME; Deen JL; von Seidlein L; Wang XY; Ampuero J; Puri M; Ali M; Ansaruzzaman M; Amos J; Macuamule A; Cavailler P; Guerin PJ; Mahoudeau C; Kahozi-Sangwa P; Chaignat CL; Barreto A; Songane FF; Clemens JD
    N Engl J Med; 2005 Feb; 352(8):757-67. PubMed ID: 15728808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding.
    Ahmed T; Svennerholm AM; Al Tarique A; Sultana GN; Qadri F
    Vaccine; 2009 Feb; 27(9):1433-9. PubMed ID: 19146904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.